诺和诺德同意以高达52亿美元的价格收购美国生物技术公司Akero Therapeutics,旨在获取后者一款前景广阔的肝病药物,从而在与肥胖相关的代谢性疾病治疗领域加码布局,以应对日益激烈的市场竞争。 周四,这家丹麦制药巨头宣布,将以每股54美元的现金预付款收购Akero,这较Akero周三46.49美元的收盘价溢价约16%。根据协议,如果该药物在2031年6月30日前就相关适应症获得美国全面批准...
Source Link诺和诺德同意以高达52亿美元的价格收购美国生物技术公司Akero Therapeutics,旨在获取后者一款前景广阔的肝病药物,从而在与肥胖相关的代谢性疾病治疗领域加码布局,以应对日益激烈的市场竞争。 周四,这家丹麦制药巨头宣布,将以每股54美元的现金预付款收购Akero,这较Akero周三46.49美元的收盘价溢价约16%。根据协议,如果该药物在2031年6月30日前就相关适应症获得美国全面批准...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.